- Home
- SDA vs SGMT Comparison
SDA vs SGMT Comparison
Compare SDA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SDA | SGMT |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | China | United States |
| Employees | 560 | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5M | 169.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SDA | SGMT |
|---|---|---|
| Price | $1.78 | $4.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.75 | ★ $26.38 |
| AVG Volume (30 Days) | ★ 455.0K | 296.4K |
| Earning Date | 04-27-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $1.73 |
| 52 Week High | $4.55 | $11.41 |
Technical Indicators
Market Signals| Indicator | SDA | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 33.00 |
| Support Level | $1.54 | N/A |
| Resistance Level | $2.18 | $6.62 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 15.62 | 0.75 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.